2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Lymphoma
201
Leukemia
159
Leukemia, Myeloid, Acute
134
Precursor Cell Lymphoblastic Leukemia-Lymphoma
132
Lymphoma, Non-Hodgkin
112
Multiple Myeloma
111
Lymphoma, Large B-Cell, Diffuse
108
Lymphoma, Follicular
93
Hodgkin Disease
92
Burkitt Lymphoma
91
Myelodysplastic Syndromes
87
Lymphoma, Mantle-Cell
87
Breast Neoplasms
85
Leukemia, Lymphocytic, Chronic, B-Cell
84
Lymphoma, Large-Cell, Immunoblastic
73
Lymphoma, B-Cell, Marginal Zone
59
Sarcoma
54
Neoplasms, Plasma Cell
50
Neuroblastoma
49
Central Nervous System Neoplasms
46
Leukemia, Myeloid, Chronic-Phase
43
Recurrence
40
Ovarian Neoplasms
39
Leukemia, Myeloid, Accelerated Phase
39
Congenital Abnormalities
39
Myeloproliferative Disorders
38
Dendritic Cell Sarcoma, Interdigitating
38
Blast Crisis
34
Leukemia, Myelomonocytic, Chronic
32
Neutropenia
29
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Radiosurgery
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Filgrastim
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts